FDA Advisory Committee recommends Afrezza for Type 1 and Type 2 Diabetes - Mannkind Corpn
MannKind Corporation has announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 Diabetes and voted 14 to 0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 Diabetes. If approved, Afrezza would be the first ultra rapid-acting mealtime insulin therapy available in the United States.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins